Effect Produced by a Cyclooctyne Derivative on Both Infarct Area and Left Ventricular Pressure via Calcium Channel Activation

Abstract

Background There are reports which indicate that some cyclooctyne derivatives may exert changes in cardiovascular system; however, its molecular mechanism is not very clear.

Objective The aim of this study was to evaluate the biological activity of four cyclooctyne derivatives (compounds 1 to 4) produced on infarct area and left ventricular pressure.

Methods Biological activity produced by cyclooctyne derivatives on infarct area was determinate using an ischemia/reperfusion injury model. In addition, to characterize the molecular mechanism of this effect, the following strategies were carried out as follows; i) biological activity produced by cyclooctyne derivative (compound 4) on either perfusion pressure or left ventricular pressure was evaluated using an isolated rat heart; ii) theoretical interaction of cyclooctyne derivative with calcium channel (1t0j protein surface) using a docking model.

Results The results showed that cyclooctyne derivative (compound 4) decrease infarct area of in a dose-dependent manner compared with compound 1 to 3. Besides, this cyclooctyne derivative increase both perfusion pressure and left ventricular pressure which was inhibited by nifedipine. Other theoretical data suggests that cyclooctyne derivative could interact with some aminoacid residues (Met₈₃, Ile₈₅, Ser₈₆, Leu₁₀₈, Glu₁₁₄) involved in 1t0j protein surface.

Conclusions All these data indicate that cyclooctyne derivative increase left ventricular pressure via calcium channel activation and this phenomenon could be translated as a decrease of infarct area.

Key words

Cyclooctyne - derivative - infarct - ischemia - calcium channel.

Publikationsverlauf

Eingereicht: 11. September 2022

Angenommen: 10. Oktober 2022

Artikel online veröffentlicht:
29. November 2022

• References

• 1 Sarajlic P, Simonsson M, Jernberg T. et al. Incidence, associated outcomes, and predictors of upper gastrointestinal bleeding following acute myocardial infarction: a SWEDEHEART-based nationwide cohort study. Eur Heart J Cardiov Pharmacother 2022; 8: 483-491
• 2 Sagris M, Antonopoulos A, Theofilis P. et al. Risk factors profile of young and older patients with Myocardial Infarction. Cardiovasr Res 2022; 118: 2281-2292
• 3 Moledina S, Shoaib A, Weston C. et al. Ethnic disparities in care and outcomes of non-ST-segment elevation myocardial infarction: a nationwide cohort study. Eur Heart J-Q Care Clin Out 2022; 8: 518-528
• 4 Collard C, Gelman S. Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. J Ame Soc Anesth 2001; 94: 1133-1138
• 5 Yellon D, Hausenloy D. Myocardial reperfusion injury. New Engl J Med 2007; 357: 1121-1135
• 6 Van’t Hof A, Liem A, Suryapranata H. et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Circulation 1998; 97: 2302-2306
• 7 Verma S, Fedak P, Weisel R. et al. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation 2002; 105: 2332-2336
• 8 Liu H, Wang C, Qiao Z. et al. Protective effect of curcumin against myocardium injury in ischemia reperfusion rats. Pharm Biol 2017; 55: 1144-1148
• 9 Yaoita H, Ogawa K, Maehara K. et al. Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation 1998; 97: 276-281
• 10 Liang Z, Liu L, Yao T. et al. Cardioprotective effects of Guanxinshutong (GXST) against myocardial ischemia/reperfusion injury in rats. J Geriat Cardiol 2012; 9: 130
• 11 Fancelli D, Abate A, Amici R. et al. Cinnamic anilides as new mitochondrial permeability transition pore inhibitors endowed with ischemia-reperfusion injury protective effect in vivo. J Med Chem 2014; 57: 5333-5347
• 12 Van Zandt M, Whitehouse D, Golebiowski A. et al. Discovery of (R)-2-amino-6-borono-2-(2-(piperidin-1-yl) ethyl) hexanoic acid and congeners as highly potent inhibitors of human arginases I and II for treatment of myocardial reperfusion injury. J Med Chem 2013; 56: 2568-2580
• 13 Zhang H, Zhang R, Liao X. et al. Discovery of β-Carboline Derivatives as a Highly Potent Cardioprotectant against Myocardial Ischemia-Reperfusion Injury. J Med Chem 2021; 64: 9166-9181
• 14 Clark J, Gebhart G, Gonder J. et al. The 1996 guide for the care and use of laboratory animals. ILAR J 1997; 38: 41-48
• 15 Figueroa-Valverde L, Diaz-Cedillo F, Rosas-Nexticapa M. et al. Synthesis and biological activity of two oxireno-azecin-imidazole derivatives on perfusion pressure via guanylate cyclase inhibition. Biointer Resin Appl Chem 2018; 3543-3551
• 16 Figueroa-Valverde L, Diaz-Cedillo F, Rosas-Nexticapa M. et al. Synthesis and Biological Activity of a Bis-steroid-methanocyclobuta-naphthalene-dione Derivative against Ischemia/Reperfusion Injury via Calcium Channel Activation. Anti-Inflam Anti-Allergy Agents Med Chem 2020; 19: 393-412
• 17 Quirk T. One-way analysis of variance (ANOVA). InExcel 2007 for educational and psychological statistics. 2012. Springer; New York, NY:
• 18 Sherikar A, Bhatia M, Dhavale R. Identification and Investigation of Chalcone Derivatives as Calcium Channel Blockers: Pharmacophore Modeling, Docking Studies, In vitro Screening, and 3D-QSAR Analysis. Curr Comp-Aid Drug Des 2021; 17: 676-686
• 19 Torchala M, Gerguri T, Chaleil R. et al. Enhanced sampling of protein conformational states for dynamic cross-docking within the protein-protein docking server SwarmDock. Proteins:Struct Funct Bioinform 2020; 88: 962-972
• 20 Markwardt F, Nilius B. Modulation of calcium channel currents in guinea-pig single ventricular heart cells by the dihydropyridine Bay K 8644. J Physiol 1988; 399: 559-575
• 21 Yamaguchi M, Murata T, Ramos J. The calcium channel agonist Bay K 8644 promotes the growth of human liver cancer HepG2 cells in vitro: suppression with overexpressed regucalcin. Mol Cell Biochem 2020; 472: 173-185
• 22 Figueroa-Valverde L, Rosas-Nexticapa M, Montserrat M. et al. Synthesis and Theoretical Interaction of 3-(2-oxabicyclo [7.4. 0] trideca-1 (13), 9, 11-trien-7-yn-12-yloxy)-steroid Deriva-tive with 17β-hydroxysteroid Dehydrogenase Enzyme Surface. Biointerface Res Appl Chem 2023; 13: 266
• 23 Figueroa-Valverde L, Diaz-Cedillo F, Gobato R. et al. Design and synthesis of two Strychnidin-oxiran-naphthalenol derivatives and their theoretical evaluation as noradrenaline and serotonin reuptake inhibitors. Vietnam Journal of Chemistry 2022; 60: 245-256
• 24 Lagunin A, Gloriozova T, Dmitriev A. et al. Computer evaluation of drug interactions with P-glycoprotein. Bull Exp Biol Med 2013; 154: 521-524
• 25 Banerjee P, Eckert A, Schrey A. et al. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res 2018; 46: W257-W263
• 26 Bi W, Bi Y, Xue P. et al. Novel β-carboline-tripeptide conjugates attenuate mesenteric ischemia/reperfusion injury in the rat. Eur J Med Chem 2011; 46: 2441-2452
• 27 Zocchi C, Ongini E, Conti A. et al. The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist. J Pharmacol Exp Ther 1996; 276: 398-404
• 28 Sato Y, Shimoji Y, Fujita H. et al. Studies on cardiovascular agents. 6. Synthesis and coronary vasodilating and antihypertensive activities of 1, 2, 4-triazolo [1, 5-a] pyrimidines fused to heterocyclic systems. J Med Chem 1980; 23: 927-937
• 29 Stavrovskaya I, Narayanan M, Zhang W. et al. Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. J Exp Med 2004; 200: 211-222
• 30 Mitsuyama T, Kawamata T, Yamane F. et al. Role of a synthetic pyrimidine compound, MS-818, in reduction of infarct size and amelioration of sensorimotor dysfunction following permanent focal cerebral ischemia in rats. J Neuros 2002; 96: 1072-1076
• 31 Mohsin Alvi A, Tariq Al Kury L, Umar Ijaz M. et al. Post-treatment of synthetic polyphenolic 1, 3, 4 oxadiazole compound A3, attenuated ischemic stroke-induced neuroinflammation and neurodegeneration. Biomol 2020; 10: 816
• 32 Salloum F, Ockaili R, Wittkamp M. et al. Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial KATP channels in rabbits. J Mol Cell Cardiol 2006; 40: 405-411
• 33 Imai S, Katano Y, Nakazawa M. et al. The effects of norepinephrine on the release of cyclic AMP by the isolated perfused heart of the guinea pig. Life Sci 1978; 23: 1609-1617
• 34 Salden F, Luermans J, Westra S. et al. Short-term hemodynamic and electrophysiological effects of cardiac resynchronization by left ventricular septal pacing. J Am Coll Cardiol 2020; 75: 347-359
• 35 Weishaar R, Kobylarz-Singer D, Steffen R. et al. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circulation Res 1987; 61: 539-547
• 36 Kisch-Wedel H, Kemming G, Meisner F. et al. The prostaglandins epoprostenol and iloprost increase left ventricular contractility in vivo. Intens Care Med 2003; 29: 1574-1583
• 37 Kisch-Wedel H, Kemming G, Meisner F. et al. Effect of prostaglandin I2 analogues on left ventricular diastolic function in vivo. Eur J Pharmacol 2005; 517: 208-216
• 38 Higgins C, Vatner S, Franklin DEAN, Braunwald EUGENE. Effects of prostaglandin A 1 on left ventricular dynamics in the conscious dog. Am J Physiol-Leg Cont 1972; 222: 1534-1538
• 39 Degousee N, Fazel S, Angoulvant D. et al. Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation 2008; 117: 1701-1710
• 40 Meena V, Meena D, Rathore P. et al. Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates-A randomized controlled trial. Ann Pediat Cardiol 2020; 13: 130
• 41 Tan S, Shapiro R, Franco R. et al. Indomethacin-induced prostaglandin inhibition with hyperkalemia: a reversible cause of hyporeninemic hypoaldosteronism. Ann Int Med 1979; 90: 783-785
• 42 Von der Saal W, Hoelck J, Kampe W. et al. Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles. J Med Chem 1989; 32: 1481-1491
• 43 Figueroa-Valverde L, Lopez-Ramos M, Rosas-Nexticapa M. et al. Experimental, theoretical and biological activity of a triazonine-derivative on left ventricular pressure. Cardiovasc Hematol Agents Med Chemy 2016; 14: 125-133
• 44 Lorell B, Paulus W, Grossman W. et al. Modification of abnormal left ventricular diastolic properties by nifedipine in patients with hypertrophic cardiomyopathy. Circulation 1982; 65: 499-507
• 45 Joshi P, Dalal J, Ruttley M. et al. Nifedipine and left ventricular function in beta-blocked patients. Heart 1981; 45: 457-459
• 46 Paulus W, Lorell B, Craig W. et al. Comparison of the effects of nitroprusside and nifedipine on diastolic properties in patients with hypertrophic cardiomyopathy: altered left ventricular loading or improved muscle inactivation?. J Am Coll Cardiol 1983; 2: 879-886
• 47 Liu Y, Grimm M, Dai W. et al. CB-Dock: a web server for cavity detection-guided protein-ligand blind docking. Acta Pharmacol Sinica 2020; 41: 138-144
• 48 Kasmi R, Hadaji E, Chedadi O. et al. 2D-QSAR and docking study of a series of coumarin derivatives as inhibitors of CDK (anticancer activity) with an application of the molecular docking method. Heliyon 2020; 6: e04514
• 49 Zhang W, Bell E, Yin M. et al. EDock: blind protein–ligand docking by replica-exchange monte carlo simulation. J Cheminform 2020; 12: 1-17
• 50 Torchala M, Gerguri T, Chaleil R. et al. Enhanced sampling of protein conformational states for dynamic cross-docking within the protein-protein docking server SwarmDock. Protein Struct Funct Bioinform 2020; 88: 962-972
• 51 Kong R, Yang G, Xue R. et al. COVID-19 Docking Server: A meta server for docking small molecules, peptides and antibodies against potential targets of COVID-19. Bioinform 2020; 36: 5109-5111
• 52 Quignot C, Postic G, Bret H. et al. InterEvDock3: a combined template-based and free docking server with increased performance through explicit modeling of complex homologs and integration of covariation-based contact maps. Nucleic Acids Res 2021; 49: W277-W284
• 53 Xu X, Zou X. Predicting Protein-Peptide Complex Structures by Accounting for Peptide Flexibility and the Physicochemical Environment. J Chem Inform Model 2021; 62: 27-39
• 54 Hu H, Wang Z, Wei R. et al. The molecular architecture of dihydropyrindine receptor/L-type Ca2⁺channel complex. Sci Rep 2015; 5: 1-6
• 55 Rutwick Surya U, Praveen N. A molecular docking study of SARS-CoV-2 main protease against phytochemicals of Boerhavia diffusa Linn. For novel COVID-19 drug discovery. Virus Dis 2021; 32: 46-54
• 56 Kumar A, Srivastava G, Negi A. et al. Docking, molecular dynamics, binding energy-MM-PBSA studies of naphthofuran derivatives to identify potential dual inhibitors against BACE-1 and GSK-3β. J Biomol Struc Dyn 2019; 37: 275-290
• 57 Levitt D. PK Quest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol. BMC Clin Pharmacol 2002; 2: 1-21
• 58 Ishaku S, Bakare-55 Odunola, M Musa A, et al. Effect of dihydro-artemisinin on the pharmacokinetics of gliclazide in diabetic subjects. Int J Biol Chem Sci 2020; 14: 2267-2276
• 59 Sicak Y. Design and antiproliferative and antioxidant activities of furan-based thiosemicarbazides and 1, 2, 4-triazoles: their structure-activity relationship and SwissADME predictions. Med Chem Res 2021; 30: 1557-1568